SMARCA4 and non-small cell lung carcinoma: Similar to our results, Schoenfeld et al. reported that NSCLC patients with KRAS/SMARCA4 class 1 co-mutations were significantly associated with poorer survival (HR = 1.59; 95% CI: 1.04–2.41; p < 0.001) compared to KRAS-mutated/SMARCA4 wild-type tumors [13].